公开(公告)号：US20220195117A1

公开(公告)日：2022-06-23

申请号：US17567420

申请日：2022-01-03

Applicant: Universite de Liege

Inventor： Christophe Detrembleur ,  Jean-Michel THOMASSIN ,  Bruno GRIGNARD ,  Florent MONIE ,  Christine JEROME

IPC: C08G71/04 ,  C08J9/08

Abstract: The present invention relates to a curable isocyanate-free formulation for preparing a polyurethane self-blowing foam comprising at least one multifunctional cyclic carbonate having at least two cyclic carbonate groups at the end of the chain (compound A), at least one multifunctional amine (compound B), at least one multifunctional thiol (compound C) and at least one catalyst (compound D), to a process for preparing said foams, to the thus obtained foams and the recycling of said foams.

公开(公告)号：US20210061804A1

公开(公告)日：2021-03-04

申请号：US16958023

申请日：2019-02-14

Applicant: UNIVERSITE DE LIEGE

Inventor： Patrizio LANCELLOTTI ,  Cécile OURY ,  Bernard PIROTTE

IPC: C07D473/40 ,  C07D473/28 ,  A61K9/00

Abstract: Pyrimidine derivatives of formula (I): optionally with a detectable isotope, pharmaceutical composition and method of preparation thereof. Pyrimidine derivatives for use in treatment or prevention of bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. Pyrimidine derivatives for use as radiotracer in diagnosing or prognosing bacterial infection in a host mammal.

公开(公告)号：US20190194213A1

公开(公告)日：2019-06-27

申请号：US16331920

申请日：2017-07-25

Applicant: Universite de Liege

Inventor： Cécile Oury ,  Patrizio Lancellotti

IPC: C07D487/04 ,  A61L27/54 ,  A61P31/04

CPC classification number: C07D487/04 ,  A01N43/90 ,  A61L27/54 ,  A61L2300/404 ,  A61L2300/406 ,  A61L2430/20 ,  A61P31/04

Abstract: Triazolo(4,5-d)pyrimidine derivatives for use in treatment or prevention of bacterial infection in a host mammal in need of such treatment or use as inhibitor of biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers.

公开(公告)号：US09993487B2

公开(公告)日：2018-06-12

申请号：US14672831

申请日：2015-03-30

Applicant: Universite de Liege ,  Paul Maes

Inventor： Didier Cataldo ,  Brigitte Evrard ,  Gilles Dufour ,  Pascal de Tullio ,  Paul Maes

IPC: A61K31/58 ,  A61K31/56 ,  A61K31/573 ,  C08B37/16 ,  C08L5/16 ,  A61K9/00 ,  A61K31/57 ,  A61K47/40 ,  A61K47/69

CPC classification number: A61K31/58 ,  A61K9/0073 ,  A61K31/56 ,  A61K31/57 ,  A61K31/573 ,  A61K47/40 ,  A61K47/6951 ,  C08B37/0015 ,  C08L5/16

Abstract: The present invention relates to novel and useful pharmaceutical compositions formulated with a cyclodextrin compound and a budesonide derivative for the treatment and/or prevention of pulmonary inflammatory disease. The present invention also relates to a novel and useful analytical technique for the detection and the quantification of HP-β-CD in solution. More specifically, the present invention relates to the use of a validated 1H NMR analysis for the detection and quantification of cyclodextrins directly in pharmaceutical formulations without any extraction or separation steps for liquid formulations.

公开(公告)号：US20160285079A1

公开(公告)日：2016-09-29

申请号：US15033622

申请日：2014-10-31

Applicant: PRAYON S.A. ,  UNIVERSITE DE LIEGE

Inventor： Dimitri Liquet ,  Cedric Calberg ,  David Eskenazi ,  Carlos Paez ,  Jean-Paul Pirard ,  Benoit Heinrichs ,  Christelle Alie

IPC: H01M4/1391 ,  H01M4/485 ,  H01M4/04 ,  H01M4/525 ,  H01M4/66 ,  H01M4/131 ,  H01M4/505

CPC classification number: H01M4/1391 ,  H01M4/0404 ,  H01M4/0409 ,  H01M4/0414 ,  H01M4/0419 ,  H01M4/0471 ,  H01M4/0497 ,  H01M4/131 ,  H01M4/485 ,  H01M4/505 ,  H01M4/525 ,  H01M4/661 ,  H01M4/662 ,  H01M4/663 ,  H01M4/664 ,  H01M4/667 ,  H01M4/669 ,  H01M2004/028

Abstract: A method produces thin films. The method includes preparing a solution containing transition metal oxide precursors, a chelating agent, and a polar organic solvent. The solution is agitated in order to form a sol. The sol is used in the form of the transition metal oxide film. The chelating agent is selected from among di- or tri-aliphatic carboxylic acids, or salts or mixtures thereof. The polar organic solvent has a boiling temperature at atmospheric pressure of less than 150° C.

Abstract translation: 一种方法产生薄膜。 该方法包括制备含有过渡金属氧化物前体，螯合剂和极性有机溶剂的溶液。 搅拌溶液以形成溶胶。 该溶胶以过渡金属氧化物膜的形式使用。 螯合剂选自二或三脂族羧酸，或其盐或其混合物。 极性有机溶剂的沸点在大气压下小于150℃。

公开(公告)号：US09238035B2

公开(公告)日：2016-01-19

申请号：US14395465

申请日：2013-04-08

Applicant: UNIVERSITE DE LIEGE

Inventor： Jean-Michel Foidart ,  Ekaterine Tskitishvili

IPC: A61K31/565 ,  A61K31/567

CPC classification number: A61K31/567 ,  A61K31/565

Abstract: The invention relates to the prophylactic and therapeutic applications of certain estrogenic components, such as estetrol, in neurological disorders, such as neonatal hypoxic-ischemic encephalopathy (HIE).

Abstract translation: 本发明涉及某些雌激素成分（例如雌激素）在神经系统疾病如新生儿缺氧缺血性脑病（HIE）中的预防和治疗应用。

公开(公告)号：US20150182499A1

公开(公告)日：2015-07-02

申请号：US14643442

申请日：2015-03-10

Applicant: Karla HADOT ,  Adrien PAGANO ,  UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) ,  UNIVERSITE DE LIEGE

Inventor： Michele REBOUD-RAVAUX ,  Chahrazade YERROUM-EL AMRI ,  Xiao TAN ,  Lixian QIN ,  Maurice PAGANO ,  Alain HOVNANIAN ,  Laetitia FURIO ,  Bernard PIROTTE

IPC: A61K31/37 ,  A61K31/4725 ,  A61K31/4433

CPC classification number: A61K31/37 ,  A61K31/4433 ,  A61K31/4725 ,  C07D311/12 ,  C07D311/14 ,  C07D405/12

Abstract: A compound of formula (I-1) wherein n equals 0 or 1, Z represents O or S, R1 represents one group chosen among the group consisting of hydrogen, C1-C7 alkyl, substituted, or not, by a halogen, a hydroxyl or a —O—R12 group, wherein R12 is a C1-C7 alkyl, a group —CH2—O—CO—R5 wherein R5 is chosen among a hydrogen atom and a C1-C7 alkyl, substituted or not by at least one halogen, a group —O—R13, wherein R13 is chosen among hydrogen and a C1-C7 alkyl, an amine or a —CH2-amine, R′1 represents a group chosen among hydrogen and —O—R14, wherein R14 is chosen among hydrogen and a C1-C7 alkyl, and R2 is chosen among the group consisting of a C1-C7 alkyl, a C3-C6 cycloalkyl, an aryl group, and an heteroaryl group for the treatment of pathologies involving excess activity of at least one member of the kallikrein family.

Abstract translation: 式（I-1）的化合物，其中n等于0或1，Z表示O或S，R1表示选自氢，C1-C7烷基，被取代或未被卤素取代的一个基团，羟基 或-O-R 12基团，其中R 12是C 1 -C 7烷基，基团-CH 2 -O-CO-R 5，其中R 5选自氢原子和C 1 -C 7烷基，被至少一个卤素 ，基团-O-R13，其中R13选自氢和C1-C7烷基，胺或-CH2-胺，R'1表示选自氢和-O-R14中的基团，其中R14选自 氢和C 1 -C 7烷基，R 2选自C 1 -C 7烷基，C 3 -C 6环烷基，芳基和杂芳基，用于治疗涉及至少一种成员的过量活性的病态 的激肽释放酶家族。

公开(公告)号：US11261270B2

公开(公告)日：2022-03-01

申请号：US16630282

申请日：2018-07-11

Applicant: KURARAY CO., LTD. ,  UNIVERSITE DE LIEGE

Inventor： Takumi Takayama ,  Kazuhiko Maekawa ,  Christophe Detrembleur ,  Antoine Debuigne ,  Christine Jerome

IPC: C08F16/06 ,  C08F2/38 ,  C08F8/12

Abstract: A polyvinyl alcohol has a number-average molecular weight (Mn) from 4,400 to 440,000, a molecular weight distribution (Mw/Mn) from 1.05 to 1.70, a degree of saponification from 80 to 99.99 mol %, wherein the polyvinyl alcohol contains an end group represented by a formula (I) below, and a molar ratio (X) of the end group based on total monomer units and the number-average molecular weight (Mn) satisfy a formula (1) below. Such a polyvinyl alcohol has a narrow molecular weight distribution and a high number-average molecular weight with hue good. (In the formula, R1 denotes an optionally substituted aromatic group having a carbon number from 6 to 20, and R2 denotes a hydrogen atom, an alkyl group having a carbon number from 1 to 20, or an optionally substituted aromatic group having a carbon number from 6 to 20.) X·Mn/44≥0.5  (1)

公开(公告)号：US20200216584A1

公开(公告)日：2020-07-09

申请号：US16630282

申请日：2018-07-11

Applicant: KURARAY CO., LTD. ,  UNIVERSITE DE LIEGE

Inventor： Takumi TAKAYAMA ,  Kazuhiko MAEKAWA ,  Christophe DETREMBLEUR ,  Antoine DEBUIGNE ,  Christine JEROME

IPC: C08F16/06 ,  C08F8/12 ,  C08F2/38

Abstract: A polyvinyl alcohol has a number-average molecular weight (Mn) from 4,400 to 440,000, a molecular weight distribution (Mw/Mn) from 1.05 to 1.70, a degree of saponification from 80 to 99.99 mol %, wherein the polyvinyl alcohol contains an end group represented by a formula (I) below, and a molar ratio (X) of the end group based on total monomer units and the number-average molecular weight (Mn) satisfy a formula (1) below. Such a polyvinyl alcohol has a narrow molecular weight distribution and a high number-average molecular weight with hue good. (In the formula, R1 denotes an optionally substituted aromatic group having a carbon number from 6 to 20, and R2 denotes a hydrogen atom, an alkyl group having a carbon number from 1 to 20, or an optionally substituted aromatic group having a carbon number from 6 to 20.) X·Mn/44≥0.5  (1)

公开(公告)号：US10385372B2

公开(公告)日：2019-08-20

申请号：US15510863

申请日：2015-09-17

Applicant: University of Florida Research Foundation, Inc. ,  UNIVERSITE DE LIEGE

Inventor： Rosemary Loria ,  Samuel Jourdan ,  Sebastien Rigali ,  Isolde Maria Francis

IPC: C12N9/42 ,  A01N43/60 ,  A01N63/02 ,  C07K14/36 ,  C12N15/10 ,  C12P17/16 ,  C07D403/06

Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in some aspects, relate to genetically modified Streptomyces bacteria capable of increased thaxtomin production, genetically modified Streptomyces bacteria with reduced activity of a CebR protein encoded by a cebR gene and/or reduced activity of a β-glucosidase enzyme encoded by the bglC gene, genetically modified Streptomyces bacteria including a mutation of a native cebR gene and/or a native bglC gene, methods of increasing thaxtomin production in Streptomyces bacteria, methods of suppressing CebR and/or BglC activity, methods of producing thaxtomin, and thaxtomin produced by the methods of the present disclosure.